İrem Demiray

Dr. İrem Demiray

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2026 in Life
Verified
Journal Article
Open access
PDF file
SKSedat Karaca
Sedat Karaca
UKUmit Kahraman
Umit Kahraman
AKAysen Yaprak Kapkın
Aysen Yaprak Kapkın
ADAhmet Daylan
Ahmet Daylan
OTOsman Nuri Tuncer
Osman Nuri Tuncer
TYTahir Yagdi
Tahir Yagdi
Background: Long-term real-world data after HeartMate 3 implantation remain limited, particularly regarding age-specific outcomes. We evaluated on-device survival and major adverse events across nearly a decade of experience. Methods: This retrospective single-center study included 215 patients undergoing primary HeartMate 3 implantation between January 2016 and October 2025. On-device mortality was analyzed using Aalen–Johansen cumulative incidence estimates with heart transplantation as a competing event; age-group differences were assessed using Fine–Gray regression. Transplant-censored Kaplan–Meier survival was examined secondarily, and mortality predictors were evaluated using multivariable Cox regression. Results: Median age was 53 years and median support was 603 days. At data cutoff, 149 patients remained alive on support, eight underwent transplantation, and 58 died on support. At 5 years, the cumulative incidences of on-device death and heart transplantation were 35.3% and 4.1%, respectively, with no significant age-group difference (Fine–Gray global p = 0.088). In the secondary transplant-censored Kaplan–Meier analysis, estimated survival was 87.4% at 30 days, 81.1% at 1 year, and 63.8% at 5 years. Higher preoperative creatinine was associated with mortality (HR, 1.93 per 1-mg/dL increase; 95% CI, 1.07–3.50; p = 0.029). No intrinsic pump thrombosis occurred. Conclusions: HeartMate 3 provided durable support with favorable long-term survival, although non-pump adverse events remained clinically relevant.

25 September 2026 in Life
Verified
Journal Article
Open access
PDF file
ÜKÜmit Kahraman
Ümit Kahraman
İDİrem Demiray
İrem Demiray
SESerkan Ertugay
Serkan Ertugay
EOEmrah Oğuz
Emrah Oğuz
OYOguz Yavuzgil
Oguz Yavuzgil
TYTahir Yagdi
Tahir Yagdi
Perceval Plus and TAVI are increasingly used for severe aortic stenosis, both relying on a self-expanding nitinol stent design, yet evidence specific to Perceval Plus remains limited regarding postoperative clinical outcomes and hematological and inflammatory dynamics. We compared postoperative clinical outcomes and longitudinal platelet/CRP dynamics between Perceval Plus and TAVI in a retrospective single-center cohort, in which 26 propensity score-matched pairs were obtained (1:1 matching) from patients undergoing Su-AVR (Perceval Plus, n = 53) or TAVI (self-expanding Medtronic devices, n = 101). Mortality, echocardiographic outcomes, and rates of postoperative atrial fibrillation and conduction disturbances showed no statistically significant differences between groups, while TAVI was associated with shorter ICU and hospital stay and Su-AVR required higher FFP transfusion (p = 0.016). Platelet count declined in both groups, with a deeper nadir in Su-AVR (postoperative day 3: 66% decline) versus TAVI (day 4: 27% decline), with a significant group × time interaction (p = 0.013); CRP rose in both groups but more rapidly and to a greater magnitude in Su-AVR (time and group × time interaction, both p < 0.001). Su-AVR and TAVI showed no statistically significant differences in the clinical safety outcomes assessed but differed in postoperative hematological and inflammatory magnitude, likely reflecting multifactorial procedure- and device-related mechanisms, warranting confirmation in larger, prospective, multicenter studies.